Drug Trial Radar · NCT07573943
ASC22 Combined With Peg-IFNa in Achieving Functional Cure in Patients With Chronic Hepatitis B Virus Infection
Last checked: Nov 20, 2026Latest source record: Sep 1, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
120
Planned (sponsor's estimate)
Start
May 21, 2024
Primary completion
Dec 31, 2026
Study completion Dec 31, 2026
Sponsor
- Lead sponsor
- The Second Affiliated Hospital of Chongqing Medical UniversityAcademic, hospital or other
- Sponsor type
- Academic, hospital or other
- First posted
- May 7, 2026
Design
- Study type
- Interventional
- Phase
- Phase 4
- Allocation
- Non randomized
- Model
- Parallel
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- All sexes, from 18 years, up to 60 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
Exploring the safety and efficacy of the therapy combining immune checkpoint inhibitors (anti-PD-L1 monoclonal antibody, ASC22) and pegylated interferon alfa (Peg-IFNα) in patients with CHB. Exploring new combination therapeutic schemes for hepatitis B cure, and raising the overall clinical cure rate to more than 50% without screening specific advantageous groups.
Conditions
- Chronic Hepatitis b
Interventions
Anti-PD-L1 antibody (ASC22)Drug
Once two weeks, 1mg/kg, subcutaneous injection
Nucleotide analogsDrug
Once/day, 1 capsule/time, oral
Peg-IFNαDrug
Once/week, 180μg/time, subcutaneous injection
Primary outcomes
What the sponsor says the trial is designed to measure.
- Serum Hepatitis B surface antigen (HBsAg) levelTime frame: Baseline
- Serum HBsAgTime frame: 24 weeks after the treatment
- Serum HBsAgTime frame: 48 weeks after the treatment
- Serum HBsAgTime frame: 24 weeks after the end of treatment
- Serum HBV DNATime frame: Baseline
- Serum HBV DNATime frame: 24 weeks after the treatment
- Serum HBV DNATime frame: 48 weeks after the treatment
- Serum HBV DNATime frame: 24 weeks after the end of treatment
- Serum alanine aminotransferase (ALT)Time frame: Baseline
- Serum alanine aminotransferase (ALT)Time frame: 24 weeks after the treatment
- Serum alanine aminotransferase (ALT)Time frame: 48 weeks after the treatment
- Serum alanine aminotransferase (ALT)Time frame: 24 weeks after the end of treatment
Locations
1 site in 1 country. Site status is shown where the registry gives one.
The 2nd affiliated Hospital of Chongqing Medical University
Chongqing, Chongqing Municipality, China · Recruiting
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.